INTRODUCTION

Facet joint pain is defined in a functional capacity as pain originating from a facet joint, and is a common cause of low back pain, with a prevalence rate ranging from 15% to 52% (1-4). Clinical symptoms and radiological findings related to facet joint syndrome are unreliable for the diagnosis of facet joint pain, so that the diagnosis “facet joint syndrome” is made clinically and by excluding other causes of low back pain (5, 6).

Facet joint pain can be managed by nonsurgical interventions, including intra-articular facet joint steroid injections, medial branch blocks, neurolysis of medial branch nerves, and radiofrequency denervation of medial branch nerves. Of these interventions, intra-articular facet joint steroid injection is helpful...
for the diagnosis (7, 8) and management (9-11) of facet joint syndrome. The use of intra-articular steroid injections is currently increasing (12). However, its usage is controversial with respect to the management of chronic low back pain. Some systematic reviews have concluded that there is only limited evidence that intra-articular facet joint steroids can be used to manage this type of pain (7, 13, 14); other reviews have suggested that there is moderate evidence of its success as a therapy (1, 15). Several studies have reported that intra-articular facet joint injection was effective in short-term follow-up, but ineffective overall in long-term follow-up, even when administered under fluoroscopic guidance (16-18).

To the best of our knowledge, no reports have yet documented the long-term results of fluoroscopically-guided intra-articular facet joint steroid injection over more than two years for large numbers of patients. Moreover, no report has yet analyzed the fluoroscopic arthograms pattern. Although several reports have analyzed outcome predictors, these studies looked at the correlation between the efficacy of intra-articular facet joint steroid injection and clinical findings in only small numbers of patients (19, 20). Similar studies to investigate outcome predictors, including fluoroscopic arthographic findings, have not yet been performed on a large numbers of patients.

The purpose of this study was therefore to evaluate, by a retrospective review of medical records and fluoroscopic arthograms, the success rate and effectiveness of fluoroscopy-guided intra-articular facet joint steroid injection for the management of low back pain. In addition, fluoroscopic arthrogram patterns and the effectiveness of the facet joint injection were also analyzed with a focus on epidural leakage.

**MATERIALS AND METHODS**

**Patient Selection**

Institutional Review Board approval was obtained, and informed consent was not required, for the retrospective review of medical records. All patients who had undergone at least one intra-articular facet joint steroid injection in 2007 were identified using a computerized database at our hospital. A total of 364 intra-articular facet joint steroid injections were performed in 281 patients in our department in 2007. The diagnosis of facet joint syndrome was based on the clinical presentation. An intra-articular facet joint steroid injection was considered for patients presenting with the following: 1) severe low back pain [verbal numeric rating score (0-10) > 5.0]; 2) low back pain that was aggravated by position change including forward flexion and extension rotation; 3) focal tenderness in the paravertebral area in the lower lumbar level; and 4) low back pain without response after more than one month of conservative treatment, such as medication and physical therapy or persistent low back pain after a previous epidural steroid injection (21).

The target site in the facet joints was selected on the basis of fluoroscopic manual compression. Under fluoroscopy, thumb pressure of the patient's lower back over the facet joint determined the tender point for the target facet joint. If the facet joint was unclear on fluoroscopic manual compression, facet joint levels near the area where the patient complained of pain were determined for injection. In the case of a postoperative facet joint injection, the injection was performed at the facet joint level, where the joint space was visualized near the focal tenderness area.

The inclusion criteria were as follows: 1) intra-articular facet joint steroid injection for low back pain, 2) fluoroscopic guidance for intra-articular injection, and 3) the presence of follow-up medical records after the injection. The exclusion criteria were as follows: 1) absence of follow-up data (n = 35 cases); 2) diagnostic facet joint block (n = 5 cases); or 3) no fluoroscopic images (n = 4 cases). A total of 320 intra-articular facet joint steroid injections in 244 patients met these criteria and were included in this investigation.

**The Intra-Articular Facet Joint Steroid Injection Technique**

One of two spine radiologists (one with one year and the other with six years of experience) from our institute performed all intra-articular facet joint steroid injections under fluoroscopic guidance. The patients lay prone on the fluoroscopy table. A uniplanar digital subtraction angiography unit (Integris Allura Xper FD 20; Philips, Best, The Netherlands) was used for fluoroscopy. Following sterile skin preparation and after a fenestrated sterile drape was placed, fluoroscopy was used to check the level and anatomy of the facet joint. Typically, a lateral to medial angulation of between 30° and 40° was necessary to visualize the facet joint space. In cases of L5–S1 facet joint injection, ad-
ditional craniocaudal angulation was used to avoid conflict between the needle tract and the iliac crest. A 22 or 25-G spinal needle was directed towards the inferior recess of the facet joint coaxial to the X-ray beam using a posterolateral approach under the oblique view of the fluoroscopy. After the needle had located the inferior recess of the facet joint, a minimal quantity of contrast agent [Omnipaque 300 (iohexol, 300 mg iodine per milliliter); Amersham Health, Princeton, NJ, USA] was injected under fluoroscopy. The intra-articular space was identified by examination of the contrast intra-articular sigmoid linear filling pattern (Fig. 1). Subsequently, 20 mg (0.5 mL) of triamcinolone acetonide suspension (Tanceton 40 mg per mL; Hanall Pharmaceutical, Seoul, Korea) and 0.5 mL bupivacaine hydrochloride (0.5 mL/0.5%; Marcaine Spinal 0.5% Heavy; AstraZeneca, Westborough, MA, USA) were injected into the intra-articular facet joint.

Follow-Up Procedure

Follow-up after the intra-articular facet joint steroid injection was routinely scheduled for 2–4 weeks, according to the patient’s condition. We told patients that they could postpone the scheduled follow-up if their symptoms were still tolerable and return to our hospital when the symptoms recurred. At follow-up, the outcome was measured on a 5-point patient satisfaction scale (no pain = virtually pain free; much improved = satisfactory effect; slightly improved = some effect but unsatisfactory; no change = ineffective; aggravated = pain provocation) and was recorded on the medical chart. The next follow-up was usually scheduled 2 or 3 months later. In accordance with the guidelines of the American Society of Interventional Pain Physicians, any kind of steroid injection was performed a maximum of six times per year in our department (22, 23).

Review of Medical Records

The items reviewed in the medical records of the patients included the age, gender, previous operation history, symptoms, date of facet joint injection, date of the first follow-up and response after facet joint injections, the presence of recurrence, symptoms controllable at last follow-up date or revisit date due to symptom recurrence, duration of symptom relief, and total number of facet joint injections. The retrospective review of the patients’ medical records was conducted by one spine radiologist in January 2010.

The symptoms were categorized as low back pain only or low back pain with leg pain. The response after an intra-articular facet joint steroid injection was based on chart documentation and determined by the 5-point patient satisfaction scale. Management after the first intra-articular facet joint steroid injection was classified as follows: observation, repeat intra-articular facet joint steroid injection, other interventions including epidural steroid injection, and others such as operation, medication, or physical therapy. If there was any symptom recurrence, it was recorded as "revisit date due to symptom recurrence". For the patients whose symptoms did not recur, the last follow-up date was recorded as "symptoms controllable at last follow-up date" for the statistical analysis of the symptom-free interval. Those patients who showed improvement after an intra-articular facet joint steroid injection, but who later had symptom recurrence, were grouped as follows: less than 30 days; 31–60 days; 61–180 days; 181–365 days; or more than 366 days.

Analysis of Fluoroscopic Arthrograms

The items reviewed in the fluoroscopic images included facet joint injection level, success of intra-articular facet joint injec-
tion, and the presence of epidural leakage after facet joint injections. Fluoroscopic arthrograms of intra-articular facet joint steroid injections were retrospectively analyzed by two radiologists in consensus.

The success of intra-articular facet joint steroid injections was grouped as follows: failure (peri-articular injection of all targeted facet joints); partial success (one or more peri-articular injection of all targeted facet joints); and complete success (intra-articular injection of all targeted facet joints).

The fluoroscopic images of facet joint injections were checked, focusing on the presence of epidural leakage (Fig. 2) after contrast injection by two radiologists in consensus. Concomitant epidural steroid injection cases (n = 98) were excluded from this analysis; in total, 222 facet joint injections were analyzed for the presence of epidural contrast leakage after an intra-articular facet joint injection.

Statistical Analysis
Outcome data were analyzed with SPSS software (SPSS, version 15; SPSS Inc., Chicago, IL, USA). To determine the median symptom-free interval after improvement from an intra-articular facet joint injection, the Kaplan-Meier method was used. “Symptoms controllable at last follow-up date” or “revisit date due to symptom recurrence” were used for the statistical analysis of the symptom-free interval. Instead of the recurrence date, we used the date of the revisit to our hospital due to symptom recurrence because the onset of the symptom recurrence was vague in most patients with chronic low back pain.

To evaluate the outcome predictors after an initial facet joint injection and the effect of epidural leakage of intra-articular facet joint injections, the responses to facet joint injection were classified as follows: positive (including no pain, much improved, and slightly improved) or negative (including no change and aggravated). Also, to evaluate the effect of epidural leakage of intra-articular facet joint injections, the duration of symptom relief after facet joint injections were classified as more than 2 months or less than 2 months. Fisher’s exact test was used for these analyses and a value of \( p < 0.05 \) was considered statistically significant.

RESULTS

Pre-Injection Data
In total, retrospective data from 320 facet joint injections of 244 consecutive patients (187 women, 57 men; mean age, 68.2 years; standard deviation, 11.3 years; age range, 20–98 years) were included in this study. Most of the 244 patients presented with chronic low back pain, including only back pain (n = 88, 36.1%) and back pain with leg pain (n = 156, 63.9%).

Response after an Initial Intra-Articular Facet Joint Steroid Injection
The initial follow-up after an intra-articular facet joint steroid

---

**Fig. 2.** A 75-year-old man underwent intra-articular facet joint steroid injection from both sides at the L4/5 level.
A. A fluoroscopic image of the left side L4/5 facet joint injection shows the intra-articular arthrographic pattern.
B, C. On oblique (B) and anteroposterior (C) fluoroscopic images of the ipsilateral side L4/5 facet joint injection, there is contrast leakage into the epidural space (arrows).
Intra-Articular Facet Joint Steroid Injection was conducted after 24.8 days on average (standard deviation, 19.3 days; range, 3–93 days). Responses according to the 5-point patient satisfaction scale are shown in Table 1. Improvement (including slightly improved, much improved, no pain) was seen in 208 patients (85.2%). Excellent improvement (including much improved, no pain) was seen in 168 patients (68.9%). In the postoperative patients, improvement (including slightly improved, much improved, no pain) was seen in 16 patients (80%). Excellent improvement (including much improved, no pain) was seen in 10 patients (50.0%). There was no statistically significant difference in the rate of pain improvement after an initial facet joint injection between the non-operative and post-operative groups ($p = 0.51$). In addition, the presence of leg pain was not statistically significant in the rate of pain improvement after an initial facet joint injection ($p = 0.71$).

Intra-articular facet joint steroid injections were repeated according to the patient’s response and willingness. Most patients only underwent an initial intra-articular facet joint steroid injection ($n = 189$, 77.5%). Repeated intra-articular facet joint injections were given four times to 6 patients (2.5%), three times to 9 patients (3.7%), and twice to 40 patients (16.4%) until December 2007.

Follow-Up and Recurrence after Serial Intra-Articular Facet Joint Steroid Injection

Among the 208 patients who showed improvement after a facet joint injection, 162 (77.9%, $n = 162/208$) showed symptom recurrence. The recurrence dates were grouped as shown in Table 2, which also includes those groups that experienced no recurrence and those with no improvement. The median symptom-free interval for cases that showed improvement after a facet joint injection was 69 days (95% confidence interval 52.2–85.8 days). Of the total 244 patients, 32% ($n = 78$) reported fewer than 60 days of pain relief, 53.3% ($n = 130$) reported more than 60 days pain relief, and 14.8% ($n = 36$) reported no pain relief. Overall, 30.3% reported a symptom-free interval of more than 6 months. In the postoperative patients, 50.0% ($n = 10$) reported fewer than 60 days of pain relief, and 30.0% ($n = 6$) reported more than 60 days of pain relief. Only 20.0% reported a symptom-free interval of more than 6 months.

Table 1. Response after an Initial Intra-Articular Facet Joint Steroid Injection

| Response               | After Initial Intra-Articular Facet Joint Injection | In Total Patients ($n = 244$) (%) | In Postoperative Patients ($n = 20$) (%) |
|------------------------|---------------------------------------------------|-----------------------------------|----------------------------------------|
| No discomfort          |                                                   | 20 (8.2)                          | 1 (5.0)                                |
| Much improved          |                                                   | 148 (60.7)                        | 9 (45.0)                               |
| Slightly improved      |                                                   | 40 (16.4)                         | 6 (30.0)                               |
| No change              |                                                   | 34 (13.9)                         | 4 (20.0)                               |
| Aggravated pain        |                                                   | 2 (0.8)                           | 0 (0)                                  |
| Total                  |                                                   | 244 (100)                         | 20 (100)                               |

Table 2. Follow-Up and Recurrence after a Serial Intra-Articular Facet Joint Steroid Injection

| Recurrence                  | Frequency | In Total Patients ($n = 244$) (%) | In Postoperative Patients ($n = 20$) (%) |
|-----------------------------|-----------|-----------------------------------|----------------------------------------|
| No improvement              |           | 36 (14.8)                         | 4 (20.0)                               |
| Temporary (< 1 month)       |           | 46 (18.9)                         | 7 (35.0)                               |
| 1–2 months                  |           | 32 (13.1)                         | 3 (15.0)                               |
| 2–6 months                  |           | 56 (23.0)                         | 2 (10.0)                               |
| 6 months–1 year             |           | 21 (8.6)                          | 1 (5.0)                                |
| > 1 year                    |           | 53 (21.7)                         | 3 (15.0)                               |
| Total                       |           | 244 (100)                         | 20 (100)                               |

Table 3. Total Numbers of Intra-Articular Facet Joint Steroid Injections Administered from 2007 to December 2009

| Total Number of Facet Joint Injection | Frequency (%) |
|---------------------------------------|---------------|
| 1                                     | 135 (55.3)    |
| 2                                     | 50 (20.5)     |
| 3                                     | 23 (9.4)      |
| 4                                     | 15 (6.1)      |
| 5                                     | 7 (2.9)       |
| > 5 (6–15)                            | 14 (5.7)      |
| Total                                 | 244 (100)     |
[partial success \(n = 15, 4.7\%\) and complete success \(n = 305, 95.3\%\)], according to the fluoroscopic arthrogram findings.

The presence of epidural leakage was found in fluoroscopic images of 74 (33.3\%) of the 222 facet joint injection cases. The responses and the duration of symptom relief after facet joint injections according to the presence of epidural leakage are shown in Table 4. There were no significant differences in the response and duration of symptom relief after facet joint injections between two groups.

**DISCUSSION**

Our results showed that approximately 85\% of patients had improvement after an initial intra-articular facet joint steroid injection; approximately 69\% of the patients showed excellent improvement after the initial injection. On the other hand, approximately 78\% of the patients showed symptom recurrence, with a median symptom-free interval of 69 days, while approximately 30\% of the patients showed a symptom-free interval of more than 6 months. One third of the intra-articular facet joint injections showed epidural contrast leakage.

According to a study by Destouet et al. (17), among 54 patients who underwent intra-articular facet joint injection, 54\% \((n = 29/94)\) immediately responded to the injection, 20\% \((n = 11/54)\) had prolonged relief, and only 11\% \((n = 6/54)\) remained free of pain for 6–12 months. Carette et al. (24) suggested that about 22\% \((n = 11)\) of 49 patients showed sustained improvement for 6 months following one intra-articular facet joint injection. Gorbach et al. (19) reported that about 74\% \((n = 31)\) of 42 patients had an immediate positive response to the intra-articular facet joint injection, whereas only 34\% \((n = 14/42)\) of these patients exhibited a positive effect after 3 months. Our results were better than those reported previously: 85\% of our patients reported an immediate response, approximately 53\% had prolonged pain relief (> 2 months), and 30\% remained free of pain for more than 6 months. These results could be due to variety of factors including patient selection bias, the precise injection technique under fluoroscopy, and checking the intra-articular location of the needle by arthrography.

Lynch and Taylor (25) suggested that the intra-articular facet joint injection is more effective than the pericapsular injection. Obtaining a better therapeutic effect for the intra-articular injection was theoretically thought to be important because the facet joint pain may be caused by synovitis inside the joint (25-27). Based on the previous studies that demonstrated the involvement of inflammatory mediators in degenerative facet joints to explain facet joint pain, we suggest that intra-articular facet joint steroid injections may provide intermediate-term pain relief in those patients whose pain is accompanied by an active inflammatory process (17, 28-30).

This study included the intra-articular facet joint injection of postoperative patients. The immediate effectiveness of this injection was similar to that of the intra-articular facet joint injection in the total patients. In addition, the symptom-free interval of the postoperative patients was similar to that of the total patients.

The success rate of the intra-articular facet joint steroid injection under fluoroscopic guidance was excellent (100\%) in our study. These results demonstrate that we could easily approach the intra-articular space of the facet joint under fluoroscopy guidance.

According to our study, epidural leakage was found frequently during intra-articular facet joint steroid injection. To our knowledge, only two studies have previously reported the occurrence of epidural leakage during such an injection. Shih et al. (31) and Schulte et al. (16) reported an incidence of approximately 1\% \((n = 3/39\) and \(n = 3/277)\) on the basis of clinical and radiological

---

**Table 4. Response and Recurrence According to the Presence of Epidural Leakage after Intra-Articular Facet Joint Steroid Injections**

| After Intra-Articular Facet Joint Injection | Epidural Leakage (+) \((n = 74)\) (%) | Epidural Leakage (-) \((n = 148)\) (%) | \(p\)-Value |
|------------------------------------------|-----------------------------------|-----------------------------------|-------------|
| Response | | | |
| Positive (including no discomfort, much improved, and slightly improved) | 65 (87.8) | 123 (83.1) | 0.432 |
| Negative (including no change and aggravated pain) | 9 (12.2) | 25 (16.9) | 0.776 |
| Recurrence | | | |
| Less than 2 months | 39 (52.7) | 74 (50.0) | |
| More than 2 months | 35 (47.3) | 74 (50.0) | |
In our study because we assumed that intra-articular facet joint steroid injection has diagnostic and therapeutic implications. In addition, if we included only patients who were diagnosed by a diagnostic facet joint block, the study would have shown better results. Thirdly, we could not analyze the effectiveness of epidural leakage and investigate the conservative treatment of patients, such as with medication or physical therapy, because the characteristics of the patients who were included in this study were heterogeneous. We suggest that a control study is needed. In addition, the leakage to the back muscles could not be included in our assessment of the epidural leakage of the facet joint injection because we retrospectively reviewed the fluoroscopic images and the leakage to the back muscles is difficult to differentiate from the diagnostic contrast injection during the approach to the facet joints.

In conclusion, this study showed that fluoroscopy-guided intra-articular facet joint injection exhibits excellent immediate effectiveness and good prolonged pain relief (>2 months) in patients with chronic low back pain; moreover, it is a reliable and easy technique for the management of low back pain. Epidural leakage during intra-articular facet joint injection was detected in approximately one-third of the cases.

REFERENCES

1. Boswell MV, Colson JD, Sehgal N, Dunbar EE, Epter R. A systematic review of therapeutic facet joint interventions in chronic spinal pain. Pain Physician 2007;10:229–253
2. Sehgal N, Shah RV, McKenzie-Brown AM, Everett CR. Diagnostic utility of facet (zygapophysial) joint injections in chronic spinal pain: a systematic review of evidence. Pain Physician 2005;8:211–224
3. Slipman CW, Bhat AL, Gilchrist RV, Issac Z, Chou L, Lenrow DA. A critical review of the evidence for the use of zygapophysial injections and radiofrequency denervation in the treatment of low back pain. Spine J 2003;3:310–316
4. Manchikanti L, Singh V, Pampati V, Damron KS, Barnhill RC, Beyer C, et al. Evaluation of the relative contributions of various structures in chronic low back pain. Pain Physician 2001;4:308–316
5. Schwarzer AC, Aprill CN, Derby R, Fortin J, Kine G, Bogduk N. Clinical features of patients with pain stemming from...
the lumbar zygapophysial joints. Is the lumbar facet syndrome a clinical entity? *Spine (Phila Pa 1976)* 1994;19:1132-1137

6. Schwarzer AC, Wang SC, O'Driscoll D, Harrington T, Bogduk N, Laurent R. The ability of computed tomography to identify a painful zygaphophysial joint in patients with chronic low back pain. *Spine (Phila Pa 1976)* 1995;20:907-912

7. Datta S, Lee M, Falco FJ, Bryce DA, Hayek SM. Systematic assessment of diagnostic accuracy and therapeutic utility of lumbar facet joint interventions. *Pain Physician* 2009;12:437-460

8. Sehgal N, Dunbar EE, Shah RV, Colson J. Systematic review of diagnostic utility of facet (zygapophysial) joint injections in chronic spinal pain: an update. *Pain Physician* 2007;10:213-228

9. Manchikanti L, Manchikanti KN, Manchukonda R, Cash KA, Damron KS, Pampati V, et al. Evaluation of lumbar facet joint nerve blocks in the management of chronic low back pain: preliminary report of a randomized, double-blind controlled trial: clinical trial NCT00355914. *Pain Physician* 2007;10:425-440

10. Fuchs S, Erbe T, Fischer HL, Tibesku CO. Intraarticular hyaluronic acid versus glucocorticoid injections for nonradicular pain in the lumbar spine. *J Vasc Interv Radiol* 2005;16:1493-1498

11. Murtagh FR. Computed tomography and fluoroscopy guided anesthesia and steroid injection in facet syndrome. *Spine (Phila Pa 1976)* 1988;13:686-689

12. Friedly J, Chan L, Deyo R. Increases in lumbosacral injections in the Medicare population: 1994 to 2001. *Spine (Phila Pa 1976)* 2005;16:1493-1498

13. Murtagh FR. Computed tomography and fluoroscopy guided anesthesia and steroid injection in facet syndrome. *Spine (Phila Pa 1976)* 1988;13:686-689

14. Friedly J, Chan L, Deyo R. Increases in lumbosacral injections in the Medicare population: 1994 to 2001. *Spine (Phila Pa 1976)* 2005;16:1493-1498

15. Chou R, Atlas SJ, Stanos SP, Rosenquist RW. Nonsurgical interventional therapies for low back pain: a review of the evidence for an American Pain Society clinical practice guideline. *Spine (Phila Pa 1976)* 2009;34:1078-1093

16. Schulte TL, Pietilä TA, Heidenreich J, Brock M, Stendel R. Injection therapy of lumbar facet syndrome: a prospective study. *Acta Neurochir (Wien)* 2006;148:1165-1172; discussion 1172

17. Destouet JM, Gilula LA, Murphy WA, Monsees B. Lumbar facet joint injection: indication, technique, clinical correlation, and preliminary results. *Radiology* 1982;145:321-325

18. Lau LS, Littlejohn GO, Miller MH. Clinical evaluation of intra-articular injections for lumbar facet joint pain. *Med J Aust* 1985;143:563-565

19. Gorbach C, Schmid MR, Elfering A, Hodler J, Boos N. Therapeutic efficacy of facet joint blocks. *AJR Am J Roentgenol* 2006;186:1228-1233

20. Revel ME, Listrat VM, Chevalier XJ, Dougados M, Nguyen MP, Vallee C, et al. Facet joint block for low back pain: identifying predictors of a good response. *Arch Phys Med Rehabil* 1992;73:824-828

21. Peh W. Image-guided facet joint injection. *Biomed Imaging Interv J* 2011;7:1-4

22. Boswell MV, Shah RV, Everett CR, Sehgal N, McKenzie Brown AM, Abdi S, et al. Interventional techniques in the management of chronic spinal pain: evidence-based practice guidelines. *Pain Physician* 2005;8:1-47

23. Lee JW, Shin Hl, Park SY, Lee GY, Kang HS. Therapeutic trial of fluoroscopic interlaminar epidural steroid injection for axial low back pain: effectiveness and outcome predictors. *AJNR Am J Neuroradiol* 2010;31:1817-1823

24. Carette S, Marcoux S, Truchon R, Grondin C, Gagnon J, Allard Y, et al. A controlled trial of corticosteroid injections into facet joints for chronic low back pain. *N Engl J Med* 1991;325:1002-1007

25. Lynch MC, Taylor JF. Facet joint injection for low back pain. A clinical study. *J Bone Joint Surg Br* 1986;68:138-141

26. Sinclair DC, Feindel WH, Weddell G, Falconer MA. The intervertebral ligaments as a source of segmental pain. *J Bone Joint Surg Br* 1948;30B:515-521

27. Mooney V, Robertson J. The facet syndrome. *Clin Orthop Relat Res* 1976;(115):149-156

28. Cohen SP, Raja SN. Pathogenesis, diagnosis, and treatment of lumbar zygapophysial (facet) joint pain. *Anesthesiology* 2007;106:591-614

29. Willburger RE, Wittenberg RH. Prostaglandin release from lumbar disc and facet joint tissue. *Spine (Phila Pa 1976)*
요통의 치료를 위한 투시하 척추후관절내 스테로이드 주사:
치료효과와 관절조영술 소견 중심으로

김수진1·이준우1·채지원2·이근영1·유자연1·강흥식1·안중모3*

목적: 이 연구는 요통의 치료를 위해서 투시하에서 척추후관절내에 스테로이드 주사를 시행하였을 때, 성공률과 효과를 확인하고, 더불어, 투시 영상을 분석하여, 경막외공간으로의 누출의 빈도를 확인하는 것이다.

대상과 방법: 2007년에 투시하에서 척추후관절내 스테로이드 주사를 시행 받은 환자 중 추적기록이 있는 환자를 대상으로 하였다. 2010년 1월에 의무기록을 통하여 주사의 반응도를 확인하였고, 투시영상을 후향적으로 분석하여 경막외공간으로의 누출을 확인하였다.

결과: 총 244명의 환자에게서 시행한 320개의 척추후관절내 스테로이드 주사가 이 연구에 포함되었다. 85.2%(n = 208) 환자가 첫 투시하에서 척추후관절내 스테로이드 주사에 반응하였고, 77.9%(n = 162) 환자가 증상의 재발을 보였으며, 중간 무증상 기간은 69일이었다. 30.3%(n = 74) 환자에서, 6개월 이상의 무증상 기간을 보였다. 222개의 척추후관절내 스테로이드 주사 중, 33.3%(n = 74)에서 경막외공간으로의 누출이 보였다.

결론: 투시하 척추후관절내 스테로이드 주사는 요통의 치료에 있어서, 쉽고 성공적으로 접근할 수 있는 치료법이며, 단기적 및 장기적으로 좋은 효과를 보여주고 있다. 이러한 척추후관절내 주사의 1/3가량에서 경막외공간으로의 누출이 발생한다.

1서울대학교 의과대학 분당서울대학교병원 영상의학과, 2서울특별시보라매병원 영상의학과, 3Department of Radiology, University of Pittsburgh Medical Center

31. Shih C, Lin GY, Yueh KC, Lin JJ. Lumbar zygapophyseal joint injections in patients with chronic lower back pain. J Chin Med Assoc 2005;68:59-64
32. Hróbjartsson A. The uncontrollable placebo effect. Eur J Clin Pharmacol 1996;50:345-348